Background Liver-type fatty acid-binding protein (FABP1) contributes to metabolic disorders.
However, the relationship between FABP1 and hyperuricemia remains unknown. We aimed …

Objective The role of liver fatty acid-binding protein (FABP1) in obesity is presently unclear.
We investigated the association of FABP1 with obesity and the changes noted after …

Background Serum concentrations of fatty acid binding protein 4, an adipose tissue fatty acid
chaperone, have been correlated with insulin resistance and cardiovascular risk factors. The …

Background A transition G to A at codon 54 of fatty acid binding protein 2 (FABP2) results in
an amino acid substitution (ala 54 to Thr 54). This polymorphism was associated with insulin …

Objective The adipocyte/macrophage fatty acid-binding protein 4 (FABP4) has been
described as a biomarker for adiposity and metabolic syndrome (MS). The aims of this study …

Background Liver fatty acid–binding protein (FABP1) plays an inconclusive role in adiposity.
We investigated the association of serum FABP1 levels with obesity and insulin resistance in …

Background Various stresses including ischemia are known to up-regulate renal L-FABP
gene expression and increase the urinary excretion of L-FABP. In diabetic patients with …

Objective: Adipocyte fatty acid‐binding protein (A‐FABP) is a plasma biomarker recently
associated with the metabolic syndrome. The aim of these studies was to investigate …

Background: Liver steatosis is considered the onset of the non-alcoholic fatty liver disease
(NAFLD), a major public health challenge. Nevertheless, NAFLD detection and diagnosis …

Aim: Plasma adipocyte fatty acid binding protein (A‐FABP) and epidermal fatty acid binding
protein (E‐FABP) concentrations have been linked to obesity and the metabolic syndrome …